In 2022, the European Medicines Agency (EMA) recommended a record number of new active substances for marketing authorization, reflecting a growing trend in pharmaceutical innovation. This uptick signals a robust pipeline of novel therapies aimed at addressing unmet medical needs across various therapeutic areas, including oncology, neurology, and infectious diseases.
The increase in approvals is indicative of the industry’s commitment to research and development, particularly in the wake of the COVID-19 pandemic, which has accelerated the need for rapid therapeutic advancements. Regulatory bodies have streamlined processes, allowing for quicker evaluations and approvals, thereby fostering a more dynamic environment for drug development.
This trend has significant implications for B2B stakeholders in the pharma sector, including regulatory affairs, quality assurance, and supply chain management. As the landscape evolves, companies must adapt to the increasing complexity of compliance and quality standards associated with new product introductions, ensuring that they remain competitive in a rapidly changing market.
Use the database as your supply chain compass →
